The SARS-CoV-2 pandemic and asthma: What we have learned and what is still unknown

Christa McPhee; Kateryna Yevdokimova; Linda Rogers; Monica Kraft

doi:10.1016/j.jaci.2023.09.005

The SARS-CoV-2 pandemic and asthma: What we have learned and what is still unknown

Christa McPhee, Kateryna Yevdokimova, Linda Rogers, Monica Kraft

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has brought new insights into the immunologic intricacies of asthma. In this review, we discuss the epidemiology of asthma in patients infected with SARS-CoV-2 and the risk of severe infection. Type 2 inflammation had an overall protective effect against SARS-CoV-2 infection by various mechanisms summarized in this review. Asthma, intranasal, and inhaled corticosteroids decreased the angiotensin-converting enzyme 2 receptor, an important receptor for SARS-CoV-2 entry into host cells. We summarize the nuances of the treatment of type 2 inflammation despite its underlying protective effects. Research to date has shown that patients on various allergen immunotherapies and biologics do benefit from being vaccinated.

Original language	English (US)
Pages (from-to)	1376-1381
Number of pages	6
Journal	Journal of Allergy and Clinical Immunology
Volume	152
Issue number	6
DOIs	https://doi.org/10.1016/j.jaci.2023.09.005
State	Published - Dec 2023
Externally published	Yes

Keywords

ACE2 receptor
Asthma
COVID-19
allergen immunotherapy
antiviral mechanisms
biologic
exacerbations
immunophenotyping assessment of COVID-19
type 2 inflammation
vaccine

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaci.2023.09.005

Cite this

@article{d2b531091bde4e498fe6ba12a64abf4c,

title = "The SARS-CoV-2 pandemic and asthma: What we have learned and what is still unknown",

abstract = "The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has brought new insights into the immunologic intricacies of asthma. In this review, we discuss the epidemiology of asthma in patients infected with SARS-CoV-2 and the risk of severe infection. Type 2 inflammation had an overall protective effect against SARS-CoV-2 infection by various mechanisms summarized in this review. Asthma, intranasal, and inhaled corticosteroids decreased the angiotensin-converting enzyme 2 receptor, an important receptor for SARS-CoV-2 entry into host cells. We summarize the nuances of the treatment of type 2 inflammation despite its underlying protective effects. Research to date has shown that patients on various allergen immunotherapies and biologics do benefit from being vaccinated.",

keywords = "ACE2 receptor, Asthma, COVID-19, allergen immunotherapy, antiviral mechanisms, biologic, exacerbations, immunophenotyping assessment of COVID-19, type 2 inflammation, vaccine",

author = "Christa McPhee and Kateryna Yevdokimova and Linda Rogers and Monica Kraft",

note = "Publisher Copyright: {\textcopyright} 2023 American Academy of Allergy, Asthma & Immunology",

year = "2023",

month = dec,

doi = "10.1016/j.jaci.2023.09.005",

language = "English (US)",

volume = "152",

pages = "1376--1381",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - The SARS-CoV-2 pandemic and asthma

T2 - What we have learned and what is still unknown

AU - McPhee, Christa

AU - Yevdokimova, Kateryna

AU - Rogers, Linda

AU - Kraft, Monica

PY - 2023/12

Y1 - 2023/12

N2 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has brought new insights into the immunologic intricacies of asthma. In this review, we discuss the epidemiology of asthma in patients infected with SARS-CoV-2 and the risk of severe infection. Type 2 inflammation had an overall protective effect against SARS-CoV-2 infection by various mechanisms summarized in this review. Asthma, intranasal, and inhaled corticosteroids decreased the angiotensin-converting enzyme 2 receptor, an important receptor for SARS-CoV-2 entry into host cells. We summarize the nuances of the treatment of type 2 inflammation despite its underlying protective effects. Research to date has shown that patients on various allergen immunotherapies and biologics do benefit from being vaccinated.

AB - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has brought new insights into the immunologic intricacies of asthma. In this review, we discuss the epidemiology of asthma in patients infected with SARS-CoV-2 and the risk of severe infection. Type 2 inflammation had an overall protective effect against SARS-CoV-2 infection by various mechanisms summarized in this review. Asthma, intranasal, and inhaled corticosteroids decreased the angiotensin-converting enzyme 2 receptor, an important receptor for SARS-CoV-2 entry into host cells. We summarize the nuances of the treatment of type 2 inflammation despite its underlying protective effects. Research to date has shown that patients on various allergen immunotherapies and biologics do benefit from being vaccinated.

KW - ACE2 receptor

KW - Asthma

KW - COVID-19

KW - allergen immunotherapy

KW - antiviral mechanisms

KW - biologic

KW - exacerbations

KW - immunophenotyping assessment of COVID-19

KW - type 2 inflammation

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85174841683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85174841683&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2023.09.005

DO - 10.1016/j.jaci.2023.09.005

M3 - Review article

C2 - 37739069

AN - SCOPUS:85174841683

SN - 0091-6749

VL - 152

SP - 1376

EP - 1381

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 6

ER -

The SARS-CoV-2 pandemic and asthma: What we have learned and what is still unknown

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this